Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 13;25(2):102-106.
doi: 10.4274/jtgga.galenos.2024.2022-9-4.

The effect of dienogest treatment on anti-Mullerian hormone in patients with endometrioma: a 12-month follow-up study

Esra Karataş  1 , Bilal Esat Temiz  1 , Sezcan Mümüşoğlu  1 , Hakan Yaralı  1   2 , Gürkan Bozdağ  3
Affiliations

The effect of dienogest treatment on anti-Mullerian hormone in patients with endometrioma: a 12-month follow-up study

Esra Karataş et al. J Turk Ger Gynecol Assoc. .

Abstract

Objective: To assess the effect of dienogest treatment on endometrioma (OMA) size, serum anti-Mullerian hormone (AMH) levels and associated pain over a 12-month follow-up period.

Material and methods: A longitudinal cohort study of 104 patients with OMA who were treated with dienogest, between January 2017 and January 2020. Of the included patients, each had a 12-month follow-up period with transvaginal or pelvic ultrasound and measurement of serum AMH concentration at the sixth and twelfth months of follow-up. The alteration in OMA size in the sixth and twelfth months of treatment was the primary outcome measure and the alteration in AMH concentration over the same period was the secondary outcome measure. The only exclusion criterion was having surgical intervention for OMA during the follow-up period (n=44). In patients with bilateral OMA (n=21), the change in size of the largest OMA was considered in the analysis.

Results: A total of 60 patients with a mean ± standard deviation (SD) age of 31.5±8.0 years were included. The mean ± SD OMA size on the day the dienogest was started was 46.3±17.4 mm and the mean AMH level was 3.6±2.4 ng/mL. After six months, the mean OMA size had decreased to 38.6±14.0 mm, with a median difference of 7.8 mm [95% confidence interval (CI): 3.0 to 12.6; p=0.003]. The mean AMH level was 3.3±2.7 ng/mL at 6 months follow-up (95% CI: -0.2 to 0.8; p=0.23) and the average difference was 0.3 ng/mL. At the 12th-month visit, when compared with the beginning of the treatment, OMA size had again significantly decreased by a median of -8.9 mm (95% CI: -2.9 to -14.9; p=0.005), and the decline in median AMH was also significant (-0.9 ng/mL, 95% CI: -0.1 to -1.7; p=0.045). The initial mean ± SD visual analog scale pain score at the commencement of dienogest treatment was 6.3±3.4. The mean values at the sixth and twelfth months of dienogest therapy were 1.08±1.8 and 0.75±1.5, respectively (both p<0.001 compared to baseline).

Conclusion: At the sixth and twelfth months of dienogest treatment a significant decrease in OMA size and reported pain scores were observed, whereas the AMH concentrations did not change significantly.

Keywords: Endometrioma; anti-Mullerian hormone; dienogest; ovarian reserve; pelvic pain.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflict of interest is declared by the authors.

Figures

Figure 1
Figure 1
OMA size (mm) at baseline, six, and twelve months of dienogest treatment (mean ± SD) OMA: Endometrioma, SD: Standard deviation
Figure 2
Figure 2
Serum AMH (ng/mL) concentration at baseline, six, and twelve months of dienogest treatment (mean ± SD) AMH: Anti-Mullerian hormone, SD: Standard deviation
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abbas S, Ihle P, Köster I, Schubert I. Prevalence and incidence of diagnosed endometriosis and risk of endometriosis in patients with endometriosis-related symptoms: findings from a statutory health insurance-based cohort in Germany. Eur J Obstet Gynecol Reprod Biol . 2012;160(1):79–83. doi: 10.1016/j.ejogrb.2011.09.041. - DOI - PubMed
    1. Nnoaham KE, Hummelshoj L, Webster P, d’Hooghe T, de Cicco Nardone F, de Cicco Nardone C ; World Endometriosis Research Foundation Global Study of Women’s Health consortium. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril . 2014;101:927. - PubMed
    1. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril . 2014;101(4):927–35. doi: 10.1016/j.fertnstert.2014.02.012. - DOI - PubMed
    1. Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility: a committee opinion. Fertil Steril . 2012;98(3):591–8. doi: 10.1016/j.fertnstert.2012.05.031. - DOI - PubMed
    1. Farquhar C. Endometriosis. Clin Evid 2004; 2391-405. - PubMed

LinkOut - more resources